Modified binding proteins inhibiting the VEGF-A receptor interaction
AssigneeMolecular Partners AG
InventorsHans Kaspar Binz, Patrik Forrer, Michael Tobias Stumpp
Life of this patent
Estimating the term…
Abstract
The present invention relates to binding proteins specific for VEGF-A, in particular to recombinant binding proteins comprising a polyethylene glycol moiety and a binding domain, which inhibits VEGF-Axxx binding to VEGFR-2. Examples of such recombinant binding proteins are proteins which comprise an ankyrin repeat domain with the desired binding specificity, and a polyethylene glycol moiety. The binding proteins are useful in the treatment of cancer and other pathological conditions, e.g. eye diseases such as age-related macular degeneration.
Claims19
A nucleic acid molecule encoding an ankyrin repeat domain of a recombinant binding protein, wherein said ankyrin repeat domain binds vascular endothelial growth factor-A165 (VEGF-A165).
A nucleic acid molecule encoding an ankyrin repeat domain, wherein said ankyrin repeat domain binds vascular endothelial growth factor-A165 (VEGF-A165), and wherein said ankyrin repeat domain comprises the amino acids 1 to 126 of SEQ ID NO:3.
A nucleic acid molecule encoding a recombinant binding protein, wherein said binding protein comprises the amino acid sequence of SEQ ID NO:3.
Dependencies are inferred from the claim text.